{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:41:10Z","timestamp":1775083270512,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Upjohn, Pizer"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Policies to combat the COVID-19 pandemic have disrupted the screening, diagnosis, treatment, and monitoring of noncommunicable (NCD) patients while affecting NCD prevention and risk factor control.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To discuss how the first wave of the COVID-19 pandemic affected the health management of NCD patients, identify which aspects should be carried forward into future NCD management, and propose collaborative efforts among public\u2013private institutions to effectively shape NCD care models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The NCD Partnership, a collaboration between Upjohn and the European Innovation Partnership on Active and Healthy Ageing, held a virtual Advisory Board in July 2020 with multiple stakeholders; healthcare professionals (HCPs), policymakers, researchers, patient and informal carer advocacy groups, patient empowerment organizations, and industry experts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The Advisory Board identified barriers to NCD care during the COVID-19 pandemic in four areas: lack of NCD management guidelines; disruption to integrated care and shift from hospital-based NCD care to more community and primary level care; infodemics and a lack of reliable health information for patients and HCPs on how to manage NCDs; lack of availability, training, standardization, and regulation of digital health tools.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Multistakeholder partnerships can promote swift changes to NCD prevention and patient care. Intra- and inter-communication between all stakeholders should be facilitated involving all players in the development of clinical guidelines and digital health tools, health and social care restructuring, and patient support in the short-, medium- and long-term future. A comprehensive response to NCDs should be delivered to improve patient outcomes by providing strategic, scientific, and economic support.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40520-021-01922-y","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T05:02:32Z","timestamp":1627448552000},"page":"2899-2907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The role of collaborative, multistakeholder partnerships in reshaping the health management of patients with noncommunicable diseases during and after the COVID-19 pandemic"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-7003","authenticated-orcid":false,"given":"Alessandro","family":"Monaco","sequence":"first","affiliation":[]},{"given":"Amaia","family":"Casteig Blanco","sequence":"additional","affiliation":[]},{"given":"Mark","family":"Cobain","sequence":"additional","affiliation":[]},{"given":"Elisio","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Nick","family":"Guldemond","sequence":"additional","affiliation":[]},{"given":"Christine","family":"Hancock","sequence":"additional","affiliation":[]},{"given":"Graziano","family":"Onder","sequence":"additional","affiliation":[]},{"given":"Sergio","family":"Pecorelli","sequence":"additional","affiliation":[]},{"given":"Mitchell","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Jos","family":"Tournoy","sequence":"additional","affiliation":[]},{"given":"Caterina","family":"Trevisan","sequence":"additional","affiliation":[]},{"given":"Mariano","family":"Votta","sequence":"additional","affiliation":[]},{"given":"John","family":"Yfantopoulos","sequence":"additional","affiliation":[]},{"given":"Stecy","family":"Yghemonos","sequence":"additional","affiliation":[]},{"given":"Vincent","family":"Clay","sequence":"additional","affiliation":[]},{"given":"Franco","family":"Mondello Malvestiti","sequence":"additional","affiliation":[]},{"given":"Karine","family":"De Schaetzen","sequence":"additional","affiliation":[]},{"given":"Georgia","family":"Sykara","sequence":"additional","affiliation":[]},{"given":"Shaantanu","family":"Donde","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"key":"1922_CR1","doi-asserted-by":"crossref","unstructured":"NCD Countdown 2030 (2018): worldwide trends in non-communicable disease mortality and progress towards Sustainable Development Goal target 3.4. Lancet 392:1072\u20131088","DOI":"10.1016\/S0140-6736(18)31992-5"},{"issue":"4","key":"1922_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.gheart.2016.10.024","volume":"11","author":"CP Benziger","year":"2016","unstructured":"Benziger CP, Roth GA, Moran AE (2016) The global burden of disease study and the preventable burden of NCD. Glob Heart 11:393\u2013397","journal-title":"Glob Heart"},{"key":"1922_CR3","doi-asserted-by":"publisher","first-page":"e1288","DOI":"10.1016\/S2214-109X(18)30411-X","volume":"6","author":"B Cao","year":"2018","unstructured":"Cao B, Bray F, Ilbawi A et al (2018) Effect on longevity of one-third reduction in premature mortality from non-communicable diseases by 2030: a global analysis of the Sustainable Development Goal health target. Lancet Glob Health 6:e1288\u2013e1296","journal-title":"Lancet Glob Health"},{"key":"1922_CR4","doi-asserted-by":"crossref","unstructured":"Chang AY, Cullen MR, Harrington RA et al. (2020) The impact of novel coronavirus COVID-19 on noncommunicable disease patients and health systems: a review. J Intern Med\u00a0289:450-462","DOI":"10.1111\/joim.13184"},{"key":"1922_CR5","doi-asserted-by":"crossref","unstructured":"Zhou F, Yu T, Du R, et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet\u00a0395:1054\u20131062","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"1922_CR6","doi-asserted-by":"crossref","unstructured":"Onder G, Rezza G, Brusaferro S (2020) Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA\u00a0323:1775\u20131776","DOI":"10.1001\/jama.2020.4683"},{"key":"1922_CR7","doi-asserted-by":"crossref","unstructured":"Li LQ, Huang T, Wang YQ, et al. (2020)\u00a0\u00a0COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 92:577\u2013583","DOI":"10.1002\/jmv.25757"},{"key":"1922_CR8","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1093\/gerona\/glaa146","volume":"75","author":"L Palmieri","year":"2020","unstructured":"Palmieri L, Vanacore N, Donfrancesco C et al (2020) Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy. J Gerontol A Biol Sci Med Sci 75:1796\u20131800","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"1922_CR9","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.arcmed.2020.07.003","volume":"51","author":"DR Hern\u00e1ndez-Galdamez","year":"2020","unstructured":"Hern\u00e1ndez-Galdamez DR, Gonz\u00e1lez-Block M, Romo-Due\u00f1as DK et al (2020) Increased risk of hospitalization and death in patients with COVID-19 and pre-existing noncommunicable diseases and modifiable risk factors in Mexico. Arch Med Res 51:683\u2013689","journal-title":"Arch Med Res"},{"key":"1922_CR10","unstructured":"https:\/\/www.cdc.gov\/mmwr\/volumes\/69\/wr\/mm6936a4.htm. Accessed 20 Mar 2021"},{"key":"1922_CR11","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1007\/s11606-020-06025-4","volume":"35","author":"A Wright","year":"2020","unstructured":"Wright A, Salazar A, Mirica M et al (2020) The invisible epidemic: neglected chronic disease management during COVID-19. J Gen Intern Med 35:2816\u20132817","journal-title":"J Gen Intern Med"},{"key":"1922_CR12","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.2337\/dc20-1347","volume":"43","author":"P Caruso","year":"2020","unstructured":"Caruso P, Longo M, Signoriello S et al (2020) Diabetic foot problems during the COVID-19 pandemic in a tertiary care center: the emergency among the emergencies. Diabetes Care 43:e123\u2013e124","journal-title":"Diabetes Care"},{"key":"1922_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/10810730.2011.601245","volume":"16","author":"CJ Hospedales","year":"2011","unstructured":"Hospedales CJ, Jan\u00e9-Llopis E (2011) A multistakeholder platform to promote health and prevent noncommunicable diseases in the region of the Americas: the Pan American Health Organization partners forum for action. J Health Commun 16:191\u2013200","journal-title":"J Health Commun"},{"key":"1922_CR14","unstructured":"Bauer K, Boles O, Stibbe D (2010) An \u2018\u2018all-of-society\u2019\u2019 approach involving business in tackling the rise in non-communicable diseases (NCDs). In: Commonwealth Health Ministers\u2019 update 2010. London: Commonwealth Secretariat. pp 137\u2013145"},{"key":"1922_CR15","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3389\/fpsyt.2020.586524","volume":"11","author":"G de Girolamo","year":"2020","unstructured":"de Girolamo G, Bellelli G, Bianchetti A et al (2020) Older people living in long-term care facilities and mortality rates during the COVID-19 pandemic in Italy: preliminary epidemiological data and lessons to learn. Front Psychiatry. 11:1032","journal-title":"Front Psychiatry."},{"key":"1922_CR16","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1186\/1471-2458-14-575","volume":"14","author":"T Oni","year":"2014","unstructured":"Oni T, McGrath N, BeLue R et al (2014) Chronic diseases and multi-morbidity\u2013a conceptual modification to the WHO ICCC model for countries in health transition. BMC Public Health 14:575","journal-title":"BMC Public Health"},{"key":"1922_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.healthpol.2017.09.006","volume":"122","author":"K Palmer","year":"2018","unstructured":"Palmer K, Marengoni A, Forjaz MJ et al (2018) Multimorbidity care model: Recommendations from the consensus meeting of the Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle (JA-CHRODIS). Health Policy 122:4\u201311","journal-title":"Health Policy"},{"issue":"1","key":"1922_CR18","first-page":"2","volume":"1","author":"EH Wagner","year":"1998","unstructured":"Wagner EH (1998) Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract 1:2\u20134","journal-title":"Eff Clin Pract"},{"key":"1922_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/ijerph16245044","volume":"16","author":"K Palmer","year":"2019","unstructured":"Palmer K, Carfi A, Angioletti C et al (2019) A methodological approach for implementing an integrated multimorbidity care model: results from the pre-implementation stage of joint action chrodis-plus. Int J Environ Res Public Health 16:24","journal-title":"Int J Environ Res Public Health"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-021-01922-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-021-01922-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-021-01922-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T04:51:09Z","timestamp":1634791869000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-021-01922-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1922"],"URL":"https:\/\/doi.org\/10.1007\/s40520-021-01922-y","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Christine Hancock: has received financial grants from (pharmaceutical) companies and worked as a paid consultant for (pharmaceutical) companies (Novo Nordisk and Pfizer) in the past. Vincent Clay: owns shares of (pharmaceutical) companies (Pfizer and Viatris) producing drugs\/devices for use in the specialty discussed in this publication and has been employed by one of the (pharmaceutical) companies (Pfizer\/Upjohn and Viatris in the past; currently employed by Novo Nordisk). Franco Mondello: Owns shares of companies (Pfizer and Viatris) producing drugs\/devices for use in the specialty discussed in this publication and is full time employee of Viatris since Nov 16 2020. Georgia Sykara: owns shares of (pharmaceutical) companies (Pfizer and Viatris) producing drugs\/devices for use in the specialty discussed in this publication and is currently employed by one of the (pharmaceutical) companies (Upjohn Hellas SA \u2013 Division of Viatris). Sergio Pecorelli: has worked in the Advisory Board of Pfizer (Nov. 18, 2019). Jos Tournoy: has received research financial support from Pfizer-Upjohn; has worked as a paid consultant for the following pharmaceutical companies: Bayer, Pfizer, BMS, Daiichi Sankyo, Rejuvenate Biomed, Eli Lilly and Company, J&J; has been paid as a speaker by the following pharmaceutical companies: Bayer, Pfizer, BMS, Daiichi Sankyo. Caterina Trevisan: has received financial grants by Pfizer as PI of the quality improvement project \u201cA Multidisciplinary Approach to Improve Adherence to Medical Recommendations in Older Adults at Hospital Discharge\u201d. John Yfantopoulos: has received financial grants from pharmaceutical companies to conduct research in the field of Health Economics; has been paid by pharmaceutical companies to be a speaker in several scientific and academic meetings. Karine De Schaetzen: owns shares of companies (Pfizer and Viatris) producing drugs\/devices for use in the specialty discussed in this publication and is a full-time employee of Viatris since November 16, 2020. Mark Cobain: received an unrestricted medical education grant from Pfizer in 2020 to conduct research into shared decision-making in hypertensive patients. Shaantanu Donde: Owns shares of companies (Pfizer and Viatris) producing drugs\/devices for use in the specialty discussed in this publication and is full-time employee of Viatris since Nov 16 2020. Alessandro Monaco, Amaia Casteig Blanco, Elisio Costa, Nick Guldemond, Graziano Onder, Mariano Votta, Stecy Yghemonos, and Mitchell Silva have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}